US Stock MarketDetailed Quotes
TOVX Theriva Biologics
- 1.3000
- +0.0200+1.56%
Close Nov 25 16:00 ET
3.62MMarket Cap-39P/E (TTM)
1.3200High1.2600Low75.01KVolume1.2900Open1.2800Pre Close95.96KTurnover3.25%Turnover RatioLossP/E (Static)2.78MShares17.112552wk High0.15P/B3.00MFloat Cap1.220052wk Low--Dividend TTM2.31MShs Float52089843.7500Historical High--Div YieldTTM4.69%Amplitude1.2200Historical Low1.2790Avg Price1Lot Size
Theriva Biologics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating revenue | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cost of revenue | ||||||||||
| Gross profit | ||||||||||
| Operating expense | 19.39%5.04M | -24.05%4.42M | 4.13%5.39M | -0.70%21.43M | -15.03%6.22M | -15.40%4.22M | 15.80%5.82M | 21.78%5.18M | 51.19%21.58M | 38.97%7.32M |
| Selling and administrative expenses | 985.85%2.3M | -45.40%1.47M | -12.18%1.93M | -27.77%7.12M | -52.40%2.02M | -91.23%212K | 74.37%2.69M | 32.99%2.2M | 52.27%9.86M | 70.80%4.25M |
| -General and administrative expense | 985.85%2.3M | -45.40%1.47M | -12.18%1.93M | -27.77%7.12M | -52.40%2.02M | -91.23%212K | 74.37%2.69M | 32.99%2.2M | 52.27%9.86M | 70.80%4.25M |
| Research and development costs | -31.75%2.73M | -5.75%2.95M | 16.19%3.46M | 22.08%14.31M | 36.63%4.2M | 55.88%4.01M | -10.10%3.13M | 14.63%2.98M | 50.29%11.72M | 10.51%3.07M |
| Operating profit | -19.39%-5.04M | 24.05%-4.42M | -4.13%-5.39M | 0.70%-21.43M | 15.03%-6.22M | 15.40%-4.22M | -15.80%-5.82M | -21.78%-5.18M | -51.19%-21.58M | -38.97%-7.32M |
| Net non-operating interest income expense | -58.64%158K | -54.59%173K | -37.36%228K | 181.05%1.44M | -0.95%312K | 124.71%382K | 1,365.38%381K | 18,100.00%364K | 8,433.33%512K | 15,650.00%315K |
| Non-operating interest income | -58.64%158K | -54.59%173K | -37.36%228K | 181.05%1.44M | -0.95%312K | 124.71%382K | 1,365.38%381K | 18,100.00%364K | 8,433.33%512K | 15,650.00%315K |
| Other net income (expense) | -47,566.67%-2.85M | -101,625.00%-4.07M | -116.67%-1K | 107.32%3K | -300.00%-4K | 166.67%6K | 55.56%-4K | 126.09%6K | -41K | -1K |
| Gain on sale of security | -50.00%3K | 75.00%-1K | -116.67%-1K | 107.32%3K | -300.00%-4K | 166.67%6K | 55.56%-4K | 126.09%6K | ---41K | ---1K |
| Special income (charges) | ---2.85M | ---4.07M | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| -Less：Restructuring and merger&acquisition | --1.33M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| -Less:Impairment of capital assets | --1.53M | --4.07M | ---- | ---- | ---- | --0 | --0 | ---- | ---- | ---- |
| Income before tax | -101.72%-7.73M | -52.78%-8.32M | -7.43%-5.17M | 5.31%-19.99M | 15.62%-5.91M | 20.62%-3.83M | -8.66%-5.44M | -12.52%-4.81M | -47.95%-21.11M | -33.06%-7M |
| Income tax | 0 | 0 | 0 | -15.09%-1.64M | 24.01%-424K | -57.31%-527K | 32.52%-359K | -330K | -1.43M | -558K |
| Net income | -133.91%-7.73M | -63.57%-8.32M | -15.34%-5.17M | 6.79%-18.35M | 14.90%-5.49M | 26.44%-3.3M | -13.56%-5.08M | -4.80%-4.48M | -37.97%-19.69M | -22.46%-6.45M |
| Net income continuous Operations | -133.91%-7.73M | -63.57%-8.32M | -15.34%-5.17M | 6.79%-18.35M | 14.90%-5.49M | 26.44%-3.3M | -13.56%-5.08M | -4.80%-4.48M | -37.97%-19.69M | -22.46%-6.45M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -133.91%-7.73M | -63.57%-8.32M | -15.34%-5.17M | 6.79%-18.35M | 14.90%-5.49M | 26.44%-3.3M | -13.56%-5.08M | -4.80%-4.48M | -37.98%-19.69M | -22.46%-6.45M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | 0 | -95.41%340K | 0 | |||||||
| Net income attributable to common stockholders | -133.91%-7.73M | -63.57%-8.32M | -15.34%-5.17M | 8.37%-18.35M | 14.90%-5.49M | 31.61%-3.3M | -13.56%-5.08M | -4.80%-4.48M | 13.64%-20.03M | -22.46%-6.45M |
| Basic earnings per share | -40.41%-6.81 | -26.47%-10.75 | 0.00%-7.5 | 12.98%-28.5 | 26.18%-8.12 | 35.33%-4.85 | -21.43%-8.5 | 3.23%-7.5 | 31.05%-32.75 | -12.82%-11 |
| Diluted earnings per share | -40.41%-6.81 | -26.47%-10.75 | 0.00%-7.5 | 12.98%-28.5 | 26.18%-8.12 | 35.33%-4.85 | -21.43%-8.5 | 3.23%-7.5 | 31.05%-32.75 | -12.82%-11 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data